Trametinib: A Targeted Therapy in Metastatic Melanoma.

Trametinib: A Targeted Therapy in Metastatic Melanoma.

Publication date: Jun 29, 2019

Trametinib is a MEK inhibitor approved both as a single agent and in combination with dabrafenib for the treatment of BRAF V600E or V600K mutated melanoma. It is a once-daily oral medication that was approved based on progression-free survival and overall survival advantage compared to chemotherapy. Most common side effects include rash, diarrhea, peripheral edema, and fatigue. When used in combination with dabrafenib, pyrexia and nausea are also common. Most side effects can be managed effectively with dose interruptions, supportive care, and/or dose reductions. Ongoing trials are investigating the use of targeted therapy in combination with immunotherapy for cutaneous melanoma and other malignancies. The treatment landscape for metastatic melanoma continues to evolve. However, targeted therapy with trametinib remains a fast-acting and efficacious option, particularly when used in combination with dabrafenib.

Hoffner, B. and Benchich, K. Trametinib: A Targeted Therapy in Metastatic Melanoma. 24681. 2019 J Adv Pract Oncol (9):7.

Concepts Keywords
BRAF Rash diarrhea
Chemotherapy Metastatic melanoma
Diarrhea Chemotherapy
Fatigue Immunotherapy
Immunotherapy Medicine
Malignancies Clinical medicine
Melanoma Chemical compounds
Nausea Cancer treatments
Peripheral Edema B-Raf inhibitor
Pyrexia Sulfonamides
Rash Antineoplastic drugs
Supportive Care Dabrafenib
Targeted Therapy MEK inhibitor
Targeted therapy


Type Source Name
drug DRUGBANK Trametinib
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma
drug DRUGBANK Dabrafenib
disease DOID rash
disease DOID diarrhea
disease MESH edema
disease DOID cutaneous melanoma
disease MESH malignancies

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *